Sign in

Prices of crucial drugs likely to fall steeply

“We plan to cap traders’ margin at around 100% across drug categories — generic, branded, scheduled and non-scheduled,” minister of state for chemicals and fertilisers Hansraj Gangaram Ahir told HT on Tuesday.

Published on: Jan 7, 2016, 24:25:04 IST
Hindustan Times | By , New Delhi
Share
Share via
  • facebook
  • twitter
  • linkedin
  • whatsapp
Copy link
  • copy link

Drug prices may see a sharp drop with the government planning to prune the profit margins of chemists and wholesalers, a move that will especially prove to be beneficial to those battling cancer, heart, kidney and liver illnesses.

The retail price of some of the drugs is 11 times (1000%) higher than their production cost, but the government wants to lower drug prices. (Shutterstock)
The retail price of some of the drugs is 11 times (1000%) higher than their production cost, but the government wants to lower drug prices. (Shutterstock)

The retail price of some of the drugs is 11 times (1000%) higher than their production cost, but the government wants to lower drug prices.

“We plan to cap traders’ margin at around 100% across drug categories — generic, branded, scheduled and non-scheduled,” minister of state for chemicals and fertilisers Hansraj Gangaram Ahir told HT on Tuesday.

“Chemists and distributors are currently charging exorbitant margins which are as high as 1000% and above… Controlling and squeezing the margins would bring down the prices…” A notification could be sent out in the next six months, he said.

Pharma firms do not offer big margins on over- the-counter drugs such as Crocin and Disprin due to competition. But, drugs for cancer, heart conditions, HIV, and liver diseases are sold at huge margins.

There is a wide difference in the landing cost — the price at which a drug is offered to a seller — and the maximum retail price (MRP) – landing cost plus the margin — of drugs for these illnesses, the government has found.

  • Himani Chandna
    ABOUT THE AUTHOR
    Himani Chandna

    Himani Chandna is a Delhi-based journalist covering the business of healthcare, pharmaceuticals, human resources and brands

Stay updated with the latest Business News, stock market updates, petrol and diesel prices, gold and silver rates, income tax updates and major developments from India and across the world.